BIOSYNEX (ALBIO.PA) Stock Price & Overview
EPA:ALBIO • FR0011005933
Current stock price
The current stock price of ALBIO.PA is 0.85 EUR. Today ALBIO.PA is up by 0.47%. In the past month the price decreased by -0.47%. In the past year, price decreased by -39.29%.
ALBIO.PA Key Statistics
- Market Cap
- 15.938M
- P/E
- N/A
- Fwd P/E
- 1.79
- EPS (TTM)
- -4.31
- Dividend Yield
- N/A
ALBIO.PA Stock Performance
ALBIO.PA Stock Chart
ALBIO.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALBIO.PA. When comparing the yearly performance of all stocks, ALBIO.PA is a bad performer in the overall market: 85.58% of all stocks are doing better.
ALBIO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. Both the profitability and financial health of ALBIO.PA have multiple concerns.
ALBIO.PA Earnings
ALBIO.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of 475% and a revenue growth 15.05% for ALBIO.PA
ALBIO.PA Groups
Sector & Classification
ALBIO.PA Financial Highlights
Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS decreased by -41.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.5% | ||
| ROE | -160.22% | ||
| Debt/Equity | 0.31 |
ALBIO.PA Ownership
ALBIO.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 14.44 | 96.419B | ||
| SHL | SIEMENS HEALTHINEERS AG | 14.48 | 43.191B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 16.3 | 23.842B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.33 | 23.842B | ||
| 1PHIA | KONINKLIJKE PHILIPS NV | 15.63 | 23.014B | ||
| BIM | BIOMERIEUX | 19.13 | 10.86B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19.22 | 3.667B | ||
| DIA | DIASORIN SPA | 15.64 | 3.528B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 14.6 | 2.424B | ||
| 1AFX | CARL ZEISS MEDITEC AG - BR | 12.37 | 2.274B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.79 | 1.818B | ||
| DRW8 | DRAEGERWERK AG | 9.23 | 1.407B | ||
| ELN | EL.EN. SPA | 17.46 | 1.058B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALBIO.PA
Company Profile
Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Company Info
IPO: 2011-03-21
BIOSYNEX
22 Boulevard Sebastien Brant
Illkirch-Graffenstaden GRAND EST FR
Employees: 454
Phone: 33388787887
BIOSYNEX / ALBIO.PA FAQ
What does ALBIO do?
Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Can you provide the latest stock price for BIOSYNEX?
The current stock price of ALBIO.PA is 0.85 EUR. The price increased by 0.47% in the last trading session.
Does ALBIO stock pay dividends?
ALBIO.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALBIO stock?
ALBIO.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of BIOSYNEX (ALBIO.PA)?
BIOSYNEX (ALBIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.31).
Can you provide the number of employees for BIOSYNEX?
BIOSYNEX (ALBIO.PA) currently has 454 employees.
What is BIOSYNEX worth?
BIOSYNEX (ALBIO.PA) has a market capitalization of 15.94M EUR. This makes ALBIO.PA a Nano Cap stock.